Abstract
Introduction: Despite the possibility of phenotypic distinction in chronic rhinosinusitis (CRS) with or without nasal polyps (NP), patients respond differently to available treatments, whether clinical and/or surgical, denoting a distinct range of endophenotypes. It is essential to identify biomarkers that, in addition to helping in the selection of patients who will benefit from new ther…